RVMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Revolution Medicines Inc (RVMD) is a strong buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock is supported by highly positive analyst ratings, strong trial results for its key drug daraxonrasib, and a bullish technical setup. Despite negative financials, the company's recent successful capital raise and potential market opportunity in oncology make it a compelling long-term investment.
The technical indicators are bullish. The MACD is positively expanding at 6.632, and the RSI is at 88.234, indicating an overbought condition. Moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 145.646 and R2: 160.207, while support levels are at S1: 98.507 and S2: 83.946. The pre-market price is $151.02, up 1.17%, showing strong momentum.
Positive results from the RASolute 302 trial, showing significant improvements in progression-free survival and overall survival for pancreatic ductal adenocarcinoma.
Analysts have raised price targets significantly, with a consensus of strong buy ratings.
The company raised $2 billion through a public offering, providing financial stability to fund future developments.
The oncology market opportunity for daraxonrasib is estimated to exceed $5 billion in the U.S. alone.
The RSI indicates the stock is overbought, suggesting potential short-term pullback risks.
Financial performance remains negative, with a net income of -$364.89 million and EPS of -1.88 in Q4 2025.
The company reported no revenue growth in Q4 2025 but showed significant improvement in net income (up 87.54% YoY) and EPS (up 67.86% YoY). Despite negative financials, the recent $2 billion capital raise strengthens its financial position for future growth.
Analysts are overwhelmingly positive, with multiple firms raising price targets significantly (e.g., Evercore ISI to $200, Guggenheim to $175, RBC Capital to $162). Analysts describe the RASolute 302 trial results as a 'game-changer' and expect rapid adoption of daraxonrasib in oncology.
